Personal Care Products Safety Act

Issues regarding dietary supplements: Dehydroepiandrosterone Abuse Reduction Act HR 6 , 21st Century Cures Act Issues relating to regulation of cosmetics industry S.1014, Personal Care Safety Act

Client expense: Not reported · Firm income: $20,000

Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE

Federal legislation and policy affecting the handmade cosmetic industry and small businesses, including S. 1014

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and federal policy affecting small handmade cosmetic companies, including Senate legislation S 1014

Client expense: Not reported · Firm income: $30,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Federal legislation and policy affecting the handmade cosmetic industry and small businesses, including S. 1014

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and federal policy affecting small handmade cosmetic companies, including Senate legislation S 1014

Client expense: Not reported · Firm income: $30,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

S.1014 - Personal Care Products Safety Act, all sections; and H.R.4075 - Cosmetic Modernization Amendments of 2015, all sections; and H.R. ______ - Legislation that would reform federal cosmetics law.

Client expense: $200,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.1014 - Personal Care Products Safety Act, all sections; and H.R.4075 - Cosmetic Modernization Amendments of 2015, all sections; and H.R. ______ - Legislation that would reform federal cosmetics law.

Client expense: $210,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.1014 - Personal Care Products Safety Act, all sections; and H.R.4075 - Cosmetic Modernization Amendments of 2015, all sections; and H.R. ______ - Draft legislation "To Amend the Federal Food, Drug, and Cosmetic Act to Ensure the Safety of Cosmetics."

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.2463-Dispose Responsibly of your Pills (DROP) Act of 2015 S.1014-Personal Care Products Safety Act

Client expense: $462,139 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

1. Fiscal Year 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations Act to help patients by urging Congress to implement a public health agenda through the Centers for Disease Control and Prevention by requesting $1.5 million to support a psoriatic disease initiative to better understand linkages between psoriatic disease and other life-threatening health conditions and to develop effective public health strategies to better equip patients to manage their health. 2. S. 1014, the Personal Care Products Safety Act, the bill strengthens FDA authority to regulate personal care products, addresses questions about the safety of certain ingredients (use by many psoriatic disease patients), creates guidance for manufacturers, and would set a national standard for cosmetics oversight. 3. S. 2113 Crowdsourcing and Citizen Science Act of 2015, the bill would encourage and increase the use of crowdsourcing and citizen science within the federal government. 4. Patients Access to Treatments Act (H.R. 1600), the bill limits cost sharing and out-of-pocket expenses for specialty tier drugs. 5. S.1488/ H.R. 2624 The Part D Beneficiary Appeals Fairness Act, the bill would allow Medicare Part D beneficiaries to request lower co-pays for high-cost specialty drugs used to treat chronic illnesses. 6. 21st Century Cures Act, set appropriated funds for biomedical research at NIH and reforms to the FDA to develop and implement a strategic plan for biomedical research

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE

- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 2777, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - Issues related to Medicare Part B Demo - Issues related to Expanded Access in Senate Innovation Package - Issues related to Self monitoring of blood glucose meters. - HR 4075, "Cosmetic Modernization Amendments of 2015", regarding all provisions. - HR 1192, "National Clinical Care Commission Act", regarding all provisions.

Client expense: $1,460,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

S.1014 - Personal Care Products Safety Act, all sections; and H.R.4075 - Cosmetic Modernization Amendments of 2015, all sections; and H.R. ______ - Draft legislation "To Amend the Federal Food, Drug, and Cosmetic Act to Ensure the Safety of Cosmetics."

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitor the Personal Care Products Safety Act (S.1014).

Client expense: Not reported · Firm income: $50,000

Government targets: SENATE

Consumer protection and product safety standards and regulations in cosmetics industry. Personal Care Products Act, S. 1014. Cosmetic Modernization Act - H.R. 4075

Client expense: Not reported · Firm income: $20,000

Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Issues relating to the regulation of cosmetics including S. 1014, "Personal Care Products Safety Act.

Client expense: $410,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)

- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.

Client expense: Not reported · Firm income: $45,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1014, Personal Care Products Safety Act

Client expense: Not reported · Firm income: $20,000

Government targets: SENATE

Personal care and cosmetic safety Personal Care Products Safety Act S.1014 Manufacturing and supply chain transparency

Client expense: $30,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.1014- Personal Care Products Safety Act; entire bill.

Client expense: $290,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE

- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FDA regulation of cosmetics, including Good Manufacturing Practices, import safety, fragrance ingredients, national uniformity and FDA resources; H.R. 4075, Cosmetic Modernization Amendments of 2015 S. 1014, Personal Care Products Safety Act

Client expense: $300,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FDA Reform - Modernization of Cosmetic Regulations S. 1014 - Personal Care Products Safety Act Safe Cosmetics Modernization Act, H.R. 4075 Safety of Cosmetic/Personal Care/Household Cleaning Products & Ingredients FDA Regulation of OTC Drugs Ingredient Communication H.R. 1321/S. 1424 - Microbead-Free Waters Act of 2015 H.R. 1139/S. 588 - Detergent PACS Act of 2015 H.R. 5205 - Cleaning Product Right to Know Act

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

S.1014- Personal Care Products Safety Act; entire bill.

Client expense: $210,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE

S. 1014, Personal Care Product Act; cosmetic legislation H.R.34, 21st Century Cures Act (P.L.114-255) H.R. 4075, The Cosmetic Modernization Act Pallone/Lance Cosmetic Safety discussion draft

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation in the 114th Congress: S. 1014, Personal Care Products Safety Act The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would effectively regulate Personal Care Products and Cosmetics to protect the health of consumers, workers, and communities. The Breast Cancer Fund also continues to meet with staff from House offices to encourage introduction of legislation in the House to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts. S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. S. 821, BPA in Food Packaging Right to Know Act The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund supports action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers. S. 3412, Ban Poisonous Additives Act of 2016 The Breast Cancer Fund supports this legislation that would ban bisphenol-A in food containers and prevent manufacturers from replacing bisphenol-A in food containers with unsafe alternatives because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. H.R. 6269, Ban Poisonous Additives Act of 2016 The Breast Cancer Fund supports this legislation that would ban bisphenol-A in food containers and prevent manufacturers from replacing bisphenol-A in food containers with unsafe alternatives because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. H.R. 5205, Cleaning Product Right to Know Act of 2016 The Breast Cancer Fund supports this bill that would require cleaning products to be labeled with all the ingredients contained therein. The Breast Cancer Fund has been meeting with House offices to urge Members to cosponsor the bill, and also with Senate offices to urge Senators to take up the issue in the Senate. HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Fund supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Fund is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).

Client expense: Not reported · Firm income: $10,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE

Legislation and policies relating to: Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Section 2706 of the ACA regarding provider non-discrimination Policies affecting nurse practitioner education and workforce Definition of essential health benefits and provider network adequacy Health information technology and electronic health records Telehealth provisions of draft medical innovation legislation Mental health services and violence prevention Lead contamination of drinking water H.R. 6/H.R. 34 - 21st Century Cures Act H.R. 30 - Save American Workers Act H.R. 248/S. 305 - American Job Protection Act H.R. 512 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act H.R. 596 - To repeal the Patient Protection and Affordable Care Act and health care-related provisions in the Health Care and Education Reconciliation Act of 2010 H.R. 609/S. 287 - Safe Food Act H.R. 879 - Ax the Tax on Middle Class Americans' Health Plans Act H.R. 897 - Zika Vector Control Act H.R. 931 - Helping Effective Antibiotics Last (HEAL) Act H.R. 932/S. 497 - Healthy Families Act H.R. 933/S. 486 - Head Start on Vaccinations Act H.R. 1151 - USPSTF Transparency and Accountability Act of 2015 H.R 1189/S. 620 - Preserving Employee Wellness Programs Act H.R. 1209/S. 628 - Improving Access to Maternity Care Act H.R. 1372 - Home Visiting Extension Act H.R. 1462/S. 799 - Protecting Our Infants Act H.R 1517 - Stop Selling and Marketing to Our Kids E-Cigarettes (SMOKE) Act H.R. 1552 - Preservation of Antibiotics for Medical Treatment Act H.R. 1599 - Safe and Accurate Food Labeling Act H.R 1624 - Protecting Affordable Coverage for Employees (PACE) Act H.R. 2017/S. 2217 - Common Sense Nutrition Disclosure Act H.R. 2300/S. 2519 - Empowering Patients First Act of 2015 H.R. 2646 - Helping Families in Mental Health Crisis Act H.R. 2653 - American Health Care Reform Act H.R. 2690 - Including Families in Mental Health Recovery Act H.R. 2713 - Title VIII Nursing Workforce Reauthorization Act H.R. 2948 - Medicare Telehealth Parity Act H.R. 3081/S. 1778 - Telemedicine for Medicare (TELE-MED) Act H.R. 3299 - Strengthening Public Health Emergency Response Act of 2015 H.R. 3379 - Airplane Kits Act H.R. 3463 - Aligning Childrens Dental Coverage Act H.R. 3495 - Women's Public Health and Safety Act H.R. 3660 - Preventive Health Savings Act H.R. 3659 - Exchange Inclusion for a Healthy America Act H.R. 3762 - Restoring Americans Healthcare Freedom Reconciliation Act H.R. 3865/S. 2542 - Cradle Act H.R. 4276 - Behavioral Health Coverage Transparency Act H.R. 4400/S. 2512 - Adding Zika Virus to the FDA Priority Review Voucher Program Act H.R. 4479 - Families of Flint Act H.R. 4723 - Protecting Taxpayers by Recovering Improper Obamacare Subsidy Overpayments Act H.R. 4724 - Reducing Duplicative and Ineffective Federal Funding Act H.R. 4771 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2016 H.R. 5001/S. 2822 - Flexibility in Health IT Reporting (Flex-IT) Act H.R. 5003 - Improving Child Nutrition and Education Act of 2016 H.R. 5065/S. 3299 - Bottles and Breastfeeding Equipment Screening (BABES) Act H.R. 5284 - Worlds Greatest Healthcare Plan Act of 2016 H.R. 5456/S. 3065 - Family First Prevention Services Act S. 30 - Forty Hours Is Full Time Act S. 142/H.R. 1375/H.R. 3242 - Child Nicotine Poisoning Prevention Act S. 185 - Promise for Antibiotics and Therapeutics for Health (PATH) Act S. 203 - American Liberty Restoration Act S. 339 - ObamaCare Repeal Act S. 481 - Improving Regulatory Transparency for New Medical Therapies Act S. 522 - Protecting & Retaining Our Children's Health Insurance Program (PRO-CHIP) Act S. 612 - Water Infrastructure Improvements for the Nation Act S. 621 - Prevention of Antibiotic Resistance Act S. 673 - Winding Down Obamacare Act S. 674 - 21st Century Womens Health Act S. 764 - National Bioengineered Food Disclosure Standard S. 971 - Medicare Independence at Home Medical Practice Demonstration Improvement Act S. 993/H.R. 1854 - Comprehensive Justice and Mental Health Act S. 1014 - Personal Care Products Safety Act S. 1016 - Preserving Freedom and Choice in Health Care Act S. 1456 - Rural ACO Improvement Act S. 1549 - Care Planning Act S. 1793 - Promoting Physical Activity for Americans Act S. 1893 - Mental Health Awareness and Improvement Act S. 1945 - Mental Health Reform Act S. 2002/H.R. 3722 - Mental Health and Safe Communities Act S. 2045/H.R. 2050 - Middle Class Health Benefits Tax Repeal Act S. 2075 - American Worker Health Care Tax Relief Act S. 2100 - Tobacco to 21 Act S. 2153 - Provider Payment Sunshine Act S. 2173/H.R. 3712 - Improving Access to Mental Health Act S. 2218/H.R. 1218 - Personal Health Investment (PHIT) Act S. 2259 - ACO Assignment Improvement Act S. 2261 - Rural ACO Provider Equity Act S. 2343/H.R. 4155 - Telehealth Innovation and Improvement Act S. 2380 - Public Health Emergency Response and Accountability Act S. 2408/H.R. 4266 - Nurse and Health Care Worker Protection Act S. 2484 - Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act S. 2525/H.R. 4567 - Expand Excellence in Mental Health Act of 2016 S. 2609 - An original bill to amend the Agricultural Marketing Act of 1946 to require the Secretary of Agriculture to establish a national voluntary labeling standard for bioengineered foods S. 2680 - Mental Health Reform Act of 2016 S. 2687 - Plan of Safe Care Improvement Act S. 2821 - Testing, Removal, and Updated Evaluations of Lead Everywhere in America for Dramatic Enhancements that Restore Safety to Homes, Infrastructure, and Pipes (True LEADership) Act of 2016 S. 2848/H.R. 5303 - Water Resources Development Act of 2016 S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes (ECHO) Act S. 3136 - Improving Child Nutrition Integrity and Access Act of 2016 S. 3190 - Strengthening Our Rural Health Workforce Act of 2016 S. 3239 - Research to Accelerate Cures and Equity (RACE) for Children Act S. 3245 - Nursing Workforce Reauthorization Act of 2016 S. 3504 - Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act

Client expense: Not reported · Firm income: $23,450

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.

Client expense: $1,620,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office

Issues regarding dietary supplements: Dehydroepiandrosterone Abuse Reduction Act Health Freedom Act H.R.6, 21st Century Cures Act H.R.34, 21st Century Cures Act S.1014, Personal Care Products Safety Act FDA regulatory related issues

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.

Client expense: $1,630,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office

Issues related to Clean Air Act regulations, climate change, ozone protection, greenhouse gas reporting, fluorochemicals, hyrdofluorocarbons and/or refrigerants and/or the Montreal Protocol (including he Kigali amendment) and United Nations supporting language and the Paris Agreement. Issues related to natural gas. Issues related to ground-level ozone EPA regulations. EPA chemical regulations, including Significant New Alternatives Policy program regulations and EPA risk management program regulations and EPA corrosivity regulations. H.R. 1321 - Microbeads-Free Waters Act of 2015 and S. 1424 Microbeads-Free Waters Act of 2015 monitor implementation and related issues. S. 2076 - Super Pollutants Act of 2015 and H.R. 508, SUPER Act of 2015; S. 1014, Personal Care Products Safety Act and H.R. 4075, Cosmetic Modernization Amendments.

Client expense: $150,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Pipeline & Hazardous Materials Safety Administration, SENATE, State, Dept of (DOS), Surface Transportation Board (STB), Transportation, Dept of (DOT), U.S. Trade Representative (USTR), White House Office

Toxic Substances Control Act (TSCA) reauthorization legislation. S. 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act. H.R. 2576 - TSCA Modernization Act of 2015. Issues related to fluorochemicals, fluoropolymers, hydrofluorocarbons and/or Montreal Protocol and/or the Paris Agreement. EPA chemical regulations, including Significant New Use Rules and the Significant New Alternatives Policy program and EPA corrosivity regulations. Monitor: S. 1014, Personal Care Products Safety Act and H.R. 4075, Cosmetic Modernization Amendments. OSHA hazard communications issues.

Client expense: $150,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Pipeline & Hazardous Materials Safety Administration, SENATE, State, Dept of (DOS), Surface Transportation Board (STB), Transportation, Dept of (DOT), U.S. Trade Representative (USTR), White House Office

H.R.34, 21st Century Cures Act (P.L.114-255). S.1767, Combination Product Regulatory Fairness Act of 2015. H.R.2433, To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review. H.R.3381/S.1883, Childhood Cancer STAR Act. S.1014, Personal Care Products Safety Act. Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 185, Regulatory Accountability Act of 2015; H.R. 527; Small Business Regulatory Flexibility Improvements Act of 2015; H.R. 1029, EPA Science Advisory Board Reform Act of 2015; H.R. 1030, Secret Science Reform Act of 2015; H.R. 1321, Microbead-Free Waters Act of 2015; H.R. 2576; TSCA Modernization Act of 2015; H.R. 2577, Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2016; H.R. 2822, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2016; H.R. 2995, Financial Services and General Government Appropriations Act, 2016; H.R. 3977, Trash Reduction Act of 2015; H.R. 4923, American Manufacturing Competitiveness Act of 2016; H.R. 5538, Department of the Interior, Environment, and Related Agencies Appropriations Act of 2017; S. 543, EPA Science Advisory Board Reform Act of 2015; S. 544, Secret Science Reform Act of 2015; S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act; S. 700, READ Act; S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act; S. 821, BPA in Food Packaging Right to Know Act; S. 1014, Personal Care Products Safety Act; S. 1447, Sustainable Chemistry Research and Development Act of 2015; S. 2794, American Manufacturing Competitiveness Act of 2016; S. 3068, Department of the Interior, Environment, and Related Agencies Appropriations Act of 2017; FY 2016 Appropriations of Department of Interior; FY 2016 Appropriations of Environmental Protection Agency; FY 2016 Appropriations Financial Services and General Government (Green Building Policies, Phthalates, CHAP and CPSC); FY 2016 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; FY 2017 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2017 Appropriations of Department of Interior; FY 2017 Appropriations of Financial Services and General Government; FY 2017 Appropriations of Department of Labor, Health and Human Services; A Bill to Provide for the Implementation of a Sustainable Chemistry Program, and for other Purposes; Alternative Fuel Tax Assessment; Bisphenol A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus (Creation and Recruitment); Chlorinated Paraffins; CPSC; CPSC Phthalates CHAP; Design for the Environment; Energy Recovery; Flame Retardants; Fluorotechnology; Formaldehyde; Good Science; Green Building Standards; Hexavalent Chromium; Integrated Risk Information System; Labeling, including GMOs; Microbeads; Microplastics; Nanotechnology; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); OSHA Crystalline Silica Rule; Permitting Reform; Phthalates; Promoting New Manufacturing Act; Rare Earths; Risk Assessment Improvements; Report on Carcinogens and International Agency for Research on Cancer; Science Advisory Board; SNUR; Styrene; T-TIP, MTB and Trade Promotion Authority; Titanium Dioxide; Toxic Substances Control Act (TSCA)(Including Confidential Business Information) and Lautenberg Chemical Safety Act Implementation (LCSA)

Client expense: $2,860,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of

- Dextromethorphan Abuse Reduction - HR 3250, DXM Abuse Prevention Act of 2015 - Regulation of OTC drugs, devices and cosmetics - HR 4075, Cosmetic Modernization Amendments of 2015 - S.1014, The Personal Care Products Safety Act

Client expense: $779,741 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

S.__/H.R.__ (Fairness in Nursing Home Arbitration Act); draft legislation not formally introduced as of 1-01-2017; relating to the use of arbitration agreements to resolve disputes involving nursing home cases and nursing home contracts. Lobbying with regard to CMS rulemaking on mandatory pre-dispute arbitration in nursing home residency contracts. Lobbying with regard to the Consumer Financial Protection Bureau rulemaking on forced arbitration. Lobbying with regard to the Education Department Rulemaking on forced arbitration. General lobbying with regard to the Federal Communications Commission and forced arbitration. S. 1122/H.R. 2079 (Court Legal Access and Student Support (CLASS) Act of 2015); makes procedures for the enforcement of arbitration agreements inapplicable to an enrollment agreement between a student and an institution of higher education (IHE). H.R. 2087/S. 1133 (Arbitration Fairness Act); prohibits mandatory, pre-dispute arbitration in consumer contracts. General lobbying with regard to the enforceability of mandatory, pre-dispute arbitration provisions in employment and consumer contracts, including financial consumer contracts and servicemember contracts for consumer products. General lobbying with regard to the ability of consumers and injured parties to bring class actions, including limitations on the ability to bring class actions involving the securities industry. S. 3491/H.R. 6423 (Justice for Victims of Fraud Act of 2016); amends the Truth in Lending Act and the Electronic Fund Transfer Act to prohibit pre-dispute arbitration agreements with consumers (i.e., agreements to arbitrate any future disputes between parties instead of pursuing the claims in court) from being valid or enforceable in disputes related to credit card accounts or personal bank accounts that are not subject to a final judgment by a court if the credit card or bank account was not issued in response to a request or application for that account. General lobbying with regard to the regulation of pre-dispute arbitration by the Federal Communications Commission. General lobbying on consumer protection provisions related to servicemember contracts for consumer products. S.__/H.R.__ (Civil Legal Access to Strong Safeguards); draft legislation not formally introduced as of 1-01-2017; amends the Class Action Fairness Act to ensure that consumers and injured parties in a class action are treated fairly and equally. General Lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to asbestos exposure and related health and environmental issues. S. 357/H.R. 526 (Furthering Asbestos Claim Transparency Act); amends Title 11 of the United States Code to require the public disclosure by trusts established under Section 524(g) of such Title, of quarterly reports that contain detailed information regarding the receipt and disposition of claims for injuries based on exposure to asbestos, and the filing of such reports with the Executive Office for United States Trustees. H.R. 1199 (Innocent Sellers Fairness Act); prevents undue disruption of interstate commerce by limiting civil actions brought against persons whose only role with regard to a product in the stream of commerce is as a lawful seller of the product. General lobbying with regard to alternative litigation funding. H.R. 54 (Frank Lautenberg Memorial Secure Chemical Facilities Act)/S. 697 (Frank R. Lautenberg Chemical Safety for the 21st Century Act)/S.725 (Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act); amends the Toxic Substances Control Act to reauthorize and modernize that Act, and for other purposes. H.R. 2576 (TSCA Modernization Act); provides for the safe and efficient flow of chemicals in interstate and foreign commerce; specific interest in provisions that would preempt state-based causes of action. Lobbying with regard to draft legislation related to PCB exposure and liability. General lobbying with regard to pesticide regulations. General lobbying with regard to the ongoing development of a proposed TAFT-TTIP trade agreement, specific interest in effect the trade agreement would have on state-based causes of action. General lobbying with regard to warranties of Energy Star-rated products and ability of consumers to bring a class action against manufacturers of Energy Star-rated products. H.R. 504/S. 1038 (Energy Star Program Integrity Act); clarifies that no express or implied warranty is provided by reason of a disclosure relating to voluntary participation in the Energy Star program. H.R. 2030/S. 700 (READ Act); amends the Asbestos Information Act of 1988 to establish a public database of asbestos-containing products, to require public disclosure of information pertaining to the manufacture, processing, distribution, and use of asbestos-containing products in the United States. Lobbying with regard to updating generic drug labeling rulemaking and responsibilities. H.R. 2841 (FAST Generics Act of 2015); amends the Federal Food, Drug, and Cosmetic Act to prohibit the license holder of a Food and Drug Administration (FDA)-approved drug or biological product from restricting availability of the medication for testing by a product developer seeking to develop a drug, generic drug, or biosimilar, including restricting availability with a risk evaluation and mitigation strategy (REMS). S. 3056 (Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016); provides for certain causes of action relating to delays of generic drugs and biosimilar biological products. Lobbying with regard to biosimilar naming and labeling. General lobbying with regard to off-label promotion of pharmaceutical products. H.R. 3304 (Foreign Manufacturers Legal Accountability Act of 2015); Requires foreign manufacturers of products imported into the US to establish registered agents in the United States who are authorized to accept service of process against such manufacturers. S. 2506 (Restoring Statutory Rights and Interests of the States Act of 2016); amends the Federal Arbitration Act to invalidate arbitration agreements between parties in certain commercial contracts or transactions if they require arbitration of a claim for damages or injunctive relief brought by an individual or small business arising from the alleged violation of a federal or state statute, the U.S. Constitution, or a state constitution, unless the written agreement to arbitrate is entered into by both parties after the claim has arisen and pertains solely to an existing claim. S. 1014 (Personal Care Products Safety Act); amends the Federal Food, Drug, and Cosmetic Act to require cosmetics companies to register their facilities with the Food and Drug Administration (FDA) and to submit to the FDA cosmetic ingredient statements that include the amounts of a cosmetic's ingredients. H.R. 4075 (Cosmetic Modernization Amendments of 2016); amends the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic manufacturing establishments, the submission of cosmetic and ingredient statements, and the reporting of serious cosmetic adverse events. H.R. 1195 (Bureau of Consumer Financial Protection Advisory Boards Act); amends the Consumer Financial Protection Act of 2010 to establish advisory boards. General lobbying regarding altering CFPB's operational structure and rulemaking authority. H.R. 1486 (Taking Account of Bureaucrats Spending Act of 2015 (TABS Act); amends the Consumer Financial Protection Act of 2010 to bring the Bureau of Consumer Financial Protection into the regular appropriations process. H.R. 5983 (Financial CHOICE Act of 2016); repealing provisions of the Dodd-Frank Act.

Client expense: $1,150,000 · Firm income: Not reported

Government targets: Consumer Financial Protection Bureau (CFPB), Education, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE

H.R.34, 21st Century Cures Act (P.L.114-255). Innovation for Healthier Americans. Cosmetic legislation including S.1014, Personal Care Products Safety Act, H.R.4075, Cosmetic Modernization Amendments of 2015 and the Pallone/Lance Cosmetic Safety Discussion Draft.

Client expense: $220,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)

Potential health and fitness legislation, and tax reform Issues related to childhood hunger S. 418 - Promoting Health as Youth Skills in Classrooms and Life Act S. 620 - Preserving Employee Wellness Programs Act H.R. 1189 - Preserving Employee Wellness Programs Act H.R. 1218 - Personal Health Investment Today Act S. 2218 - Personal Health Investment Today Act H.R. 1270 - Restoring Access to Medication Act of 2015 S. 2296 - Workforce Health Improvement Program Act S. 1014 - Personal Care Products Safety Act S. 2499 - Health Savings Act H.R. 4469 - Health Savings Act S. 2980 - Health Savings Account Expansion Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to regulation of cosmetics industry and effect on small businesses. S.1014, Personal Care Products Safety Act.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1014, The Personal Care Product and Safety Act, and its affects on the Handcrafted Soap and Cosmetic Industry and Small Businesses. HR. 4075, a bill that seeks to update and modernize the cosmetic industry reporting requirements to the FDA and its affects on the Handcrafted Soap and Cosmetic Industry

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 1014, the Personal Care Products Safety Act; H.R.2576, the Frank R. Lautenberg Chemical Safety for the 21st Century Act; Clean Air Act, Antimicrobial Resistance

Client expense: $40,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Treasury, Dept of, U.S. Postal Service (USPS), White House Office

FDA regulation of cosmetics, including Good Manufacturing Practices; import safety; fragrance ingredients; national uniformity and FDA resources; international trade and harmonization. S. 1014, The Personal Care Products Safety Act. H.R. 4075, Cosmetic Modernization Amendments of 2015.

Client expense: Not reported · Firm income: $90,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

HR 2576, Toxic Chemical Safety Modernization Act of 2015; Endocrine-Disrupting chemicals S 697, Frank Lautenberg Chemical Safety Act for 21st Century; S. 1014 Personal Care Products Safety Act

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

HR 2576, Toxic Chemical Safety Modernization Act of 2015; Endocrine-Disrupting chemicals S 697, Frank Lautenberg Chemical Safety Act for 21st Century; S. 1014 Personal Care Products Safety Act

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE